Casirivimab and Imdevimab Administration

Name: Negotiated commercial rates for Casirivimab and Imdevimab Administration (HCPCS M0243), in Idaho
Creator: Tynbil
License: https://tynbil.com/terms

Idaho rates for HCPCS M0243

Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring

Rates data updated July 2026.

Rates by insurance carrier

Insurance Carrier	Facility/Professional	Modifier	Typical Low	Median	Typical High